26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04004819 (ClinicalTrials.gov) | August 15, 2019 | 27/6/2019 | Rituximab for HTLV-1-associated Myelopathy | Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy | HTLV-1-associated Myelopathy | Drug: Rituximab | First Affiliated Hospital of Fujian Medical University | NULL | Recruiting | 18 Years | 80 Years | All | 100 | Phase 2 | China |